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Abstract  
Cone photoreceptor cell death as it occurs in certain hereditary retinal diseases is devastating, with the 
affected patients suffering from a loss of accurate and color vision. Regrettably, these hereditary cone 
diseases are still untreatable to date. Thus, the identification of substances able to block or restrain cone 
cell death is of primary importance. We studied the neuroprotective effects of a histone deacetylase 
inhibitor, Trichostatin A (TSA), in a mouse model of inherited, primary cone degeneration (cpfl1). We 
show that HDAC inhibition protects cpfl1 cones in vitro, in retinal explant cultures. More importantly, in 
vivo, a single intravitreal TSA injection significantly increased cone survival for up to 16 days post-
injection. In addition, the abnormal, incomplete cone migration pattern in the cpfl1 retina was 
significantly improved by HDAC inhibition. These findings suggest a crucial role for HDAC activity in 
primary cone degeneration and highlight a new avenue for future therapy developments for cone 
dystrophies and retinal diseases associated with impaired cone migration. 
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Introduction  
Cone photoreceptors in the human retina are responsible for sharp high resolution vision and color 
discrimination. Hereditary cone degenerations, such as in Stargardt´s and Best´s disease, achromatopsia, 
and cone dystrophies are caused by mutations in single genes, and lead to severe visual impairment, 
reduced visual acuity and loss of color vision. Cone dystrophies are characterized by a high genetic 
heterogeneity, with disease causing mutations in at least 27 genes (RetNet: https://sph.uth.edu/retnet). In 
addition, a genetic contribution has also been proposed for complex diseases affecting cones, such as in 
age-related-macular degeneration (AMD) or diabetic retinopathy (DR). Irrespective of the genetic cause, 
a common outcome of retinal diseases is neuronal cell death, giving a strong rationale for targeted 
neuroprotective approaches that may prevent or delay cell death execution (1).  
The cone photoreceptor function loss-1 (cpfl1) mutant mouse is an animal model for autosomal 
recessive achromatopsia or progressive cone dystrophy (2). This model is unique in the sense that it is 
characterized by an early onset of cone loss at post-natal day 14 (PN14) and a fast progression with the 
peak of cell death at PN24 (3). We have previously shown that photoreceptor cell death in the cpfl1 
mouse, as well as in nine other animal models for inherited retinal degeneration, follows a non-apoptotic 
mechanism, characterized by accumulation of cGMP, increased activities of cGMP-dependent protein 
kinase (PKG), histone deacetylase (HDAC), poly-ADP-ribose-polymerase (PARP), and calpain proteases, 
as well as accumulation of poly-ADP-ribose (PAR) (4, 5). In addition, the cpfl1 cone degeneration is also 
associated with prominent defects in cone migration (3).  
A common non-apoptotic cell death mechanism in different retinal degeneration models provides a 
rationale for the identification of therapeutic targets that would prove beneficial for a broader population 
of patients suffering from a variety of different genetic causes (4, 6). While, numerous attempts to restrain 
the execution of rod photoreceptor cell death were described (6-11) to date, an effective clinical treatment 
for primary cone photoreceptor degeneration has not been reported. Since humans use mostly cones for 
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their vision, a development of treatment protocols to preserve cones is of highest priority in clinical 
ophthalmology. 
The interplay between histone acetylation and deacetylation, performed by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) respectively, determines the transcription state of genes in 
general (12), and this is also true for photoreceptor-specific genes (13, 14). Aberrant activity of histone 
deacetylases is associated with a number of diseases with very different etiology, ranging from cancer to 
neurodegenerative diseases (15). Consequently, in current medicine, HDAC inhibition is discussed as one 
of the most promising novel therapeutic approaches for various diseases (16).  
In the present study, we tested the hypothesis that hereditary cone degeneration can be prevented or 
delayed by HDAC pharmacological inhibition. We assessed cone photoreceptor survival after HDAC 
inhibition with Trichostatin A (TSA) in vitro, on retinal explant cultures obtained from cpfl1 animals, as 
well as in vivo, after intravitreal injection. We show that TSA protects cpfl1 cones both in vitro and in 
vivo. Importantly, a single TSA injection in vivo achieved a significant protection of cone photoreceptors, 
up to sixteen days post-injection. In addition, we observed a significant improvement of impaired cone 
migration, present in the degenerating cpfl1 retina. Our study highlights the possibility to use 
pharmacological HDAC inhibition for substantial cone protection in an inherited cone dystrophy, and 
may forward the future development of therapies aimed at cone photoreceptor preservation. 
 
Results 
HDAC activity is increased in cpfl1 photoreceptors 
We have previously shown that the cpfl1 cone photoreceptor degeneration follows a non-apoptotic cell 
death mechanism characterized by increased HDAC activity at the peak of degeneration at PN24 (4). In 
this study, we evaluated HDAC activity also at the onset of cone degeneration (PN14) and found 
significantly more HDAC activity positive photoreceptors in mutant retinas compared to wild-type (wt) 
(Supplementary material Fig. S1A-F). Increased HDAC activity present also at PN24 was significantly 
decreased after the TSA treatment (p=0.004; Supplementary material Fig. S1G). 
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HDAC inhibition with TSA rescues degenerating cones in vitro 
To test whether HDAC inhibition could promote cone photoreceptor survival, we used cpfl1 long-term 
retinal explants cultured under entirely defined conditions, in serum-free medium. Both cpfl1 and wt 
retinas were explanted at the onset of cpfl1 degeneration (PN14) and cultured for 2 days in regular R16 
retinal culture medium, without any treatment. Retinas were then exposed to 10 nM TSA every second 
day, until PN24. In the untreated cpfl1 explants almost half of the cones were lost at PN24, as assessed by 
the percentage of cones in the outer nuclear layer (ONL), identified by labeling with an antibody for 
glycogen phosphorylase (Glyphos) (17). When compared to untreated wt explants (n=4), only ~53% of 
cones are still present in cpfl1 retina as shown in Figure 1 (52.91% ± 7.18 SEM, n=7). Treatment with 10 
nM TSA increased the percentage of surviving cones in cpfl1 explants to wt levels (109.76% ± 10.34, 
n=6, p= 0.0023), indicating near complete cone protection. On the other hand, TSA had no significant 
effect on cone photoreceptors in wt cultures (110.27% ± 23.18 SEM, n=3). 
 
Intravitreal TSA injection protects degenerating cones in vivo 
These promising in vitro results prompted us to further evaluate the protective effects of HDAC 
inhibition in vivo. To guide and optimize the in vivo treatment scheme, we first tried to predict the 
potential half-life of the drug inside the eye. Model calculations suggested that intravitreal clearance of 
TSA in the rabbit eye was 0.478 ml/h, and the half-life was in the range of 1.7-3.3 hours. In the mouse, 
the calculated intravitreal half-life of TSA was an order of magnitude shorter (about 17 minutes), and 
more than 90% of the dose was expected to be eliminated in one hour after injection (Supplementary 
material Fig. S2 and Note 1). 
Since our in vitro experiments suggested that 10 nM TSA was efficiently protecting cones, we wanted 
to test if the same concentration would be effective also in vivo. As controls, we included both non-treated 
and sham treated eyes in the analysis. At PN14, nine animals from three different litters received an 
injection of 0.5 µl of a 100 nM TSA solution in one eye, with an estimated final TSA concentration of 10 
nM. The contralateral eyes were sham injected with vehicle to control for injection-specific effects. Mice 
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were sacrificed and analyzed 10 days later, at PN24. Consistent with our in vitro results, TSA 
significantly increased the percentage of surviving cones in treated vs. sham treated eyes (cpfl1 sham: 
84.92% ± 3.1 SEM, n=9; cpfl1 treated: 99.88% ± 4.83, n=9, p=0.026; Fig. 2). The percentage of cones in 
sham injected eyes was comparable to the percentage of cones in non-treated cpfl1 mice (cpfl1: 78.24% ± 
2.53 SEM, n=8; cpfl1 sham: 84.92% ± 3.1, n=9), suggesting that the injection itself had no effect on cone 
survival. The number of cones in sham- or 10 nM TSA- treated wt retinas were similar to non-treated wt 
retinas confirming the in vitro observation that TSA in the studied dosage had no deleterious effect on 
healthy cones (wt sham: 102.37% ± 4.72, n=8; wt treated: 106.11% ± 7.02, n=8, Fig. 2). The in vivo 
results suggested a remarkable protection of degenerating cones by a single intravitreal injection of 10 nM 
TSA with the number of cones in treated retinas reaching 99.8% of wt levels. To then test if TSA could 
efficiently protect degenerating cones at even lower concentrations, we performed a single intravitreal 
injection of TSA with a final estimated concentration of 1 nM, at PN14, and evaluated the protective 
effects at PN24. Remarkably, 1 nM TSA single treatment yielded a protective effect comparable to the 10 
nM dose (Fig. 2, cpfl1 sham: 83.24% ± 2.92 SEM, n=10; cpfl1 treated: 98.3% ± 5.25, n=11, p=0.03). 
To assess protective effect of HDAC inhibition at longer time points, we treated the cpfl1 animals with 
a single intravitreal injection of 10 nM TSA and assessed cone survival at PN30, i.e. after the peak of 
degeneration. When compared to untreated PN30 wt retina, cone loss in sham-treated cpfl1 had 
progressed further, with 71.6% ± 3.77 cones remaining (Fig. 3). In contrast, in 10 nM TSA treated eyes, 
even 16 days after a single intravitreal injection, the percentage of cones was significantly higher than in 
sham-treated, with 88.74% ± 2.79 cones still present (n=5, p=0.007). However, the protective effect at 
PN30 was less pronounced than at PN24, with the number of surviving cones lower than in wt retina 
(p=0.03). 
To understand whether the observed increase in the cone numbers after TSA treatment was due to an 
indirect effect of a reduced clearance by microglia, we assessed the status of microglia using a staining 
against ionized-calcium-binding-adapter molecule 1 (IBA1) (18). Although activated microglia appeared 
to be present to some extent in the different layers of the retina, we neither detected a microglial invasion 
 at U
nited A
rab Em
irates U
niversity on A
ugust 16, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
7 
 
of the ONL, nor differences in IBA1 positive cells, with or without TSA treatment (Supplementary 
material Fig. S3). Alternatively, the protective effect of TSA might have been related to a delay of cone 
maturation in cpfl1 animals. To address this possibility, we also characterized the status of cone 
differentiation by looking at the expression and localization of M- and S-opsins, as well as cone-specific 
transducin (GNAT2), previously reported to be abnormally distributed in degenerating cones (19). 
Although M-opsin was seen in untreated cone outer segments, cpfl1 cones frequently showed opsin 
mislocalization to the cell body (Fig. 4G, arrows) and synaptic terminals (Fig. 4G, arrowheads). S-opsin 
staining revealed short outer segments as well as opsin mislocalization (Fig. 4H, arrows) in untreated 
cpfl1 cones and a similar but more pronounced mislocalization was observed for GNAT2 (Fig. 4I, 
arrows). In contrast, double staining for M- and S-opsin with Glyphos indicated that cones protected by 
TSA had normal morphology, with clearly developed inner and outer segments (Fig. 4J-L and P-R). In 
addition, the correctly positioned cones in the upper part of the ONL show both M- and S-opsin properly 
localized in their outer segments (Fig. 4J and R). Similarly, in surviving cones GNAT2 was properly 
localized in outer segments. The correct localization of cone opsins and cone transducin suggested that 
TSA-mediated cone preservation had no obvious adverse effects on cone development and maturation. 
 
HDAC inhibition significantly improves impaired cone migration 
We previously reported that cpfl1 retina is characterized by impaired migration of developing cones 
(3). Glyphos staining of cones in degenerating cpfl1 retina confirmed such aberrant cone positioning, both 
in vitro and in vivo (Fig. 5). Importantly, we observed an improved migration of cones after both in vitro 
and in vivo TSA treatments of retinas (Fig. 5). To evaluate the extent of the cone migration improvement, 
we measured the distance of the center of individual cone nuclei from the outer plexiform layer (OPL, 
Fig. 5, dashed red lines), which demarcates the lower boundary of the photoreceptor area. The percentage 
of cone migration distance from the OPL is presented in relative terms to the thickness of the ONL. In the 
in vitro situation, at PN24, wt cones migrated approximately to 70% of ONL thickness (wt untreated: 
69.25% ± 2.3 SEM, n=3; wt treated: 72.66% ± 5.1, n=3), while in non-treated cpfl1 retinas they reached 
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only 55%. After treatment with 10 nM TSA of cpfl1 retinas in explant cultures, cone nuclei reached a 
position very similar to that of wt cones (cpfl1 untreated: 55.31% ± 3.1 SEM, n=6; cpfl1 treated: 65.95% 
± 2.8, p=0.029). Similarly, cone migration was also improved in cpfl1 retinas in vivo, after treatment with 
1 nM TSA. Here, cones were localized significantly more distant from the outer plexiform layer (cpfl1 
untreated: 71.68% ± 1.09 SEM, n=10, cpfl1 treated: 77.18% ± 0.84, n=11, p=0.02). Comparable results 
were obtained after treatment with 10 nM TSA (cpfl1 untreated: 67.47% ± 1.92 SEM, n=9, cpfl1 treated: 
76.38% ± 0.73, n=9, p=0.0005). We did not observe changes in cone localization in wt retinas after TSA 
treatment (wt untreated: 86.89% ± 0.26 SEM, n=7; wt treated: 85.49% ± 0.23, n=7). Nevertheless, even 
though TSA treatment significantly improved cpfl1 cone migration, cone positioning was still 
significantly different compared to wt cones (cpfl1 1 nM TSA: 77.18% ± 0.84 SEM vs. wt untreated: 
86.89% ± 0.26, p=0.0002; cpfl1 10nM: 76.38% ± 0.73 vs. wt untreated: 86.89% ± 0.26, p=0.0004). 
We previously found high cGMP accumulation and increased activity of cGMP-dependent protein 
kinase G (PKG) to be associated with cpfl1 cone phenotypes (3). To investigate whether HDAC 
inhibition had an effect on cGMP and PKG activity after ten days of treatment with TSA, we looked for 
cGMP accumulation and the phosphorylation status of a well-known PKG substrate, vasodilator-
stimulated-protein (pVASP) (20), with and without TSA treatment. Untreated cpfl1 retinas showed cGMP 
accumulation in cone segments as well as in cone cell bodies (as evidenced by Glyphos co-labeling). 
There were no obvious differences in cone cGMP accumulation after TSA treatment. (Supplementary 
material Fig. S4A). Likewise, some cones, visualized by Glyphos staining, were also positive for pVASP 
in both TSA treated and untreated cpfl1 retinas, with no evident differences between the two (Fig. S4B). 
Taken together, these results indicated that HDAC activity (and TSA inhibition) operated down-stream of 
the mutation-induced cGMP accumulation. 
 
Discussion 
 at U
nited A
rab Em
irates U
niversity on A
ugust 16, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
9 
 
Hereditary diseases of cone photoreceptors are currently untreatable and lead to major visual 
impairment and blindness. Our study in the cpfl1 mouse model demonstrates prominent cone protection 
after HDAC inhibition, in vitro and in vivo, and thus confirms that HDAC activity is causally involved in 
hereditary cone photoreceptor degeneration. This provides a proof-of-principle for the further 
development of HDAC inhibition as a novel therapeutic approach for cone dystrophies. 
HDAC inhibition was found to induce cell death in tumor cells derived from various cancers (21), 
while in neurodegenerative diseases, the same treatment may prolong cell survival (22). In the retina, 
HDAC inhibitors have been discussed as a potential therapeutic strategy for ischemic retinal injury, with 
different HDAC inhibitors affording structural and functional neuroprotection after experimental ischemia 
(23). Furthermore, HDAC inhibition was shown to slow rod photoreceptor degeneration in an animal 
model for Retinitis Pigmentosa (24). Importantly, current clinical trials are suggesting beneficial effects 
of treatments with a HDAC inhibitor in patients suffering from Retinitis Pigmentosa (25, 26). We show 
here for the first time that HDAC inhibition significantly protects cones in a mouse model for hereditary 
cone dystrophy. Besides its implication for future treatment of rare forms of retinal degeneration, the 
results presented here may also extend to common diseases of the retina, including DR and AMD, where 
cone degeneration is the cause of legal blindness. 
An important result from our study is that a single intraocular application significantly protected cpfl1 
cones for at least two weeks post-injection. This is unexpected, as our calculations on TSA clearance 
suggested that the drug was below threshold concentration, after less than 2 hours and may point to an 
imprinting mechanism, beyond the transient presence of TSA. This is in line with previous studies which 
found that TSA leads to robust protein acetylation after 3 hours (13) or to transcriptional changes after 
only 5 minutes (27), supporting the possibility of epigenetic mechanisms. The molecular mechanism 
underlying treatments with HDAC inhibitors are still not well characterized. In cpfl1 retina, a previous 
study found an upregulation of STAT3 signaling which was suggested as an endogenous neuroprotective 
response (28). Interestingly, STAT3 activation may be controlled by HDAC activity (29).  
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Importantly, the TSA clearance estimation suggested that cone degeneration was halted already after a 
short-time intraocular exposure. This observation could be especially relevant for patients with retinal 
dystrophies where monthly intravitreal injections are usually well tolerated (30). Since in mice the 
protective effect was present for at least 10 days post-injection, a rough extrapolation from mouse to man, 
would suggest that in humans an intravitreal dosing once per three months might be sufficient (31). 
Alternatively, formulations for local application to the eye would minimize the potential side-effects 
observed in some cases of long-term, systemic HDAC inhibition (26, 32, 33). 
Cone photoreceptor development is characterized by a migration within the ONL, from the outer 
limiting membrane inwards to the OPL, and then outwards, until they reach their final position just below 
the outer limiting membrane, from PN12 onwards (34). Cone degeneration in mouse models is 
characterized not only by cone loss, but also by improper developmental cone migration (3, 35). In fact, 
delayed cone migration was also reported in mouse models with rod degeneration as an indirect 
consequence of rod cell death (34). Migration of cone photoreceptors also occurs in human retinal 
development, where in the fovea cones are migrating laterally towards the foveal pit (36). Cone 
misplacement has been associated with human retinal diseases of different etiology as improper cone 
migration can lead to foveal hypoplasia (37). This is observed, for instance, in patients suffering from 
albinism (38), idiopathic congenital nystagmus (37), and also from achromatopsia (39). In addition, cone 
misplacement was reported in aged patients suffering from AMD (40). We found that TSA treatment not 
only prevented cone degeneration but also significantly improved aberrant cone migration in degenerating 
cpfl1 retina. There are numerous reports on the effects of HDAC inhibition on cell migration. The effects 
of HDAC inhibition on improved cell migration could take place via inhibition of the cytoplasmic histone 
deacetylase (HDAC6) resulting in higher acetylation of α-tubulin necessary for stability of microtubules 
in migrating cells (41). Alternatively, HDAC inhibition could lead to epigenetic changes governing 
migration of photoreceptors, a process still not fully understood. TSA treatment significantly improved 
the migration of misplaced cpfl1 cones both in vitro and in vivo. Nevertheless, HDAC inhibition alone 
was not sufficient to fully repair the cone migration defect in cpfl1 retinas. A plausible explanation could 
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relate to increased PKG activity in cpfl1 retina, as we previously reported (3). PKG-specific 
phosphorylation of the serine 239 residue of VASP was shown to negatively regulate neuronal migration 
(42). Proteins of the Ena/VASP family are regulators of actin assembly and cell motility as they are 
localized in focal adhesions (43). cGMP-dependent PKG overactivation leads to VASP phosphorylation, 
which will result in removal of VASP from focal adhesions, contributing to altered cell migration (44). 
Our data suggest that TSA inhibition of HDACs did not reduce VASP phosphorylation of serine 239 as 
assessed by immunostaining. The possible dual regulation of cone photoreceptor migration, one via PKG 
overactivation and the other involving aberrant HDAC activity, will require further specific studies. In 
addition, in the cpfl1 mouse model, the mutation-induced loss of cone photoreceptors coincides in part 
with postnatal retinal development (3, 45). As the TSA treatment during the third postnatal week overlaps 
in time with the establishment of retinal connectivity (46), further studies (i.e. rod ERG analysis) are also 
necessary to define how restoration of the normal developmental cone migration pattern under the 
influence of  HDAC inhibitors may alter rod connectivity and function. 
Degenerating cones in cpfl1 retina are characterized by cGMP accumulation as a consequence of the 
non-functional cone photoreceptor PDE6 enzyme (3, 4). We did not observe obvious changes in the 
numbers of cells showing cGMP accumulation after the treatment, indicating that TSA-driven protection 
of cones probably operates down-stream in the degenerative pathway. Increasing lines of evidence 
suggest PKG as one of the main initiators of a photoreceptor cell death cascade (4, 6, 47). Previously, we 
found that increased PKG and HDAC activities were temporally connected in 10 different animal models 
for inherited retinal degeneration (4). This corresponds to observations in C. elegans where PKG activity 
was found to regulate HDAC activation (48). Since HDAC inhibition did not seem to affect VASP 
phosphorylation in cones, our study indicates that during cell death HDAC activity may occur 
independently of- or downstream of PKG. The underlying mechanisms through which HDAC inhibition 
offers cone protection remains to be determined. 
HDAC activity is also crucial for mouse photoreceptor development as HDAC inhibition at early post-
natal retinal development (PN2) leads to a complete loss of developing rod photoreceptors (49). In the 
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mouse retina cone photoreceptors are born prenatally (45), therefore we do not expect an effect of TSA on 
cone birth, but the full maturation and commitment towards blue cones (S cones) or red/green cones (M 
cones) takes place during the second postnatal week (50). Since we performed HDAC inhibition just after 
this time-period, we assessed the expression and localization of S- and M-opsin, to address whether the 
observed increase in cone survival following HDAC inhibition was due to cone development and 
maturation delays. In addition, we checked for the cone specific transducin (GNAT2), a member of the 
cone phototransduction cascade (51). The observed correct localization of cone opsins and transducin 
suggests that late postnatal HDAC inhibition did not affect cone cell development and maturation. 
However, we cannot exclude the possibility that the rapid degeneration of cpfl1 cones was in part caused 
by developmental defects. In this case TSA treatment, in a critical time-frame, may have supported 
normal development as the observed effects lasted for more than two weeks. Future studies, for instance 
on more slowly progressing cone degeneration models, may reveal whether TSA and HDAC inhibition 
mediated cone protection can be applied to cone degeneration in general, irrespective of developmental 
stage and disease pathogenesis. 
In summary, this study is the first to show that HDAC inhibition can significantly delay cone loss in a 
mouse model for a human cone dystrophy. While the effect of TSA on cpfl1 retina in vivo lasts until at 
least one month post-natal, further studies will be needed to determine the duration of the protection and 
to establish long-term treatment paradigms. Remarkably, HDAC inhibition appeared to have a dual effect 
on both cone survival and cone migration without obvious effects on cone differentiation and 
development. Our study thus provides a proof-of-principle for the potential of HDAC inhibitors as 
therapeutic agents for cone photoreceptor protection. Importantly, this may be applicable not only to 
hereditary cone dystrophies, but possibly also to common retinal diseases associated with cone 
degeneration such as diabetic retinopathy (52, 53), as well to diseases where cone degeneration is 
accompanied by improper cone migration, such as age-related macular degeneration (40). 
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Materials and Methods 
Animals 
Cpfl1 and congenic C57BL/6 wild-type (wt) animals were housed under standard white cyclic 
lighting, had free access to food and water, and were used irrespective of gender. All procedures were 
approved by the Tübingen University committee on animal protection (Einrichtung für Tierschutz, 
Tierärztlichen Dienst und Labortierkunde) and performed in accordance with the ARVO statement for the 
use of animals in ophthalmic and visual research. Procedures performed at the polistab of University of 
Modena and Reggio Emilia (in vivo treatment on cpfl1 and wt animals) were reviewed and approved by 
the local ethical committee (Prot. N. 50 12/03/2010). All efforts were made to minimize the number of 
animals used and their suffering. 
 
Immunofluorescence 
Retinae were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) for 45 min at 
4°C. Sagittal 12 µm sections were collected, air-dried and stored at -20°C. Sections were incubated 
overnight at 4°C with primary antibodies. The primary antibodies used were specific for Glycogen 
phosphorylase (Glyphos, 1:1000 dilution, kindly provided by Prof. Pfeiffer-Guglielmi (17)), cone arrestin 
(1:1000, AB15282, Millipore,  Darmstadt, Germany), IBA1 (1:200, 019-19741, Wako, Richmond, USA), 
M-opsin (1:200, AB5405, Millipore), S-opsin (1:200, AB5407, Millipore), GNAT2 (1:200, sc-390, Santa 
Cruz, Dallas, USA), cGMP (1:500, kindly provided by Prof. Steinbusch, University of Maastricht, The 
Netherlands (54)) and phospho-VASP (Ser239) (1:200 dilution, 0047-100/VASP-16C2, Nanotools, 
Teningen, Germany (3, 44)). Alexa Fluor 488- or 566-conjugated were used as secondary antibodies 
(Molecular Probes, Inc. Eugene, USA). Negative controls were carried out by omitting the primary 
antibody. Specificity of cone labeling with Glyphos was shown by co-labelling with peanut-agglutinin 
(Supplementary Fig. S5), a well-established marker for cones (55).   
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HDAC in situ activity assay 
HDAC activity assays were performed on cryosections of 4% PFA- fixed eyes. The assay is based on 
an adaptation of the Fluor de Lys Fluorescent Assay System (Biomol, Hamburg, Germany). Retina 
sections were exposed to 200 µM Fluor de Lys-SIRT2 deacetylase substrate (Biomol) with 500 µM 
NAD+ (Biomol) in assay buffer (50 mM Tris/HCl, 137 mM NaCl; 2.7 mM KCl; 1 mM MgCl2; pH 8.0) 
for 3 hours at room temperature (8). Sections were then washed in PBS and fixed in methanol at -20°C 
for 20 min. Slides were mounted with developer (Biomol; KI105, diluted 1:20 in assay buffer) containing 
2 µM TSA (Sigma, Steinheim, Germany) and 2 mM NAM (Sigma). Negative controls consisted of 
omitting the substrate (Supplementary Fig.S1E). 
 
Retinal explant cultures 
Organotypic retinal cultures from cpfl1 (n=7) and wt (n=4) animals that included the retinal pigment 
epithelium (RPE) were prepared under sterile conditions. Briefly, PN14 animals were sacrificed, the eyes 
enucleated and pretreated with 0.12% proteinase K (ICN Biomedicals Inc., OH, USA) for 15 minutes at 
37°C in R16 serum free culture medium (Order No.: 074-90743A; Gibco, Paisley, UK). Proteinase K 
activity was blocked by addition of 10% fetal bovine serum, followed by rinsing in serum-free medium. 
Following this, the cornea, lens, sclera and choroid were removed carefully, with only the RPE remaining 
attached to the retina. The explant was then cut into four wedges, to give a clover-leaf like structure, 
which was transferred to a culture membrane insert (Corning Life Sciences, Lowell, USA) with the RPE 
facing the membrane. The membrane inserts were placed into six well culture plates with R16 medium 
(Gibco, Paisley, UK) and incubated at 37°C in a humidified 5% CO2 incubator. The culture medium was 
changed every 2 days during the 10 culturing days.  
Retinal explants were left without treatment for 2 days (until PN16), followed by 10 nM Trichostatin 
A (TSA) treatment (≥98% (HPLC), from Streptomyces sp., Sigma-Aldrich, St-Louis, USA). TSA was 
dissolved in 0.2% dimethyl sulfoxide (DMSO; Sigma) and diluted in R16 culture medium. For controls, 
the same amount of DMSO was diluted in culture medium. Culturing was stopped at PN24 by 2 h fixation 
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in 4% PFA, cryoprotected with graded sucrose solutions containing 10, 20, and 30% sucrose and then 
embedded in tissue freezing medium (Leica Microsystems Nussloch GmbH, Nussloch, Germany). 
 
In vivo injections 
Animals were anesthetized with an intraperitoneal injection of Avertin (250 mg/kg) (1.25% (w/v) 
2,2,2-tribromoethanol and 2.5% (v/v) 2-methyl-2-butanol; Sigma, Milan, IT) and kept warm during 
injections. Single intravitreal injections were performed at PN14 on one eye while the other eye was sham 
injected with 0.0001% DMSO (in 0.9% NaCl solution) as contralateral control. TSA (1 and 10 nM) was 
diluted in 0.9% NaCl solution. Injections were performed with 0.5 µl of 10 nM and 100 nM TSA in order 
to have a final concentration of 1 nM and 10 nM, respectively, assuming the free intraocular volume of 
mouse eye to be 5µl (http://prometheus.med.utah.edu/~marclab/protocols.html). Eleven cpfl1 animals and 
eight wt from three different litters were used for intravitreal injections and were sacrificed 10 days after 
treatment (PN24). For the treatment of cpfl1 animals until PN30 injections were performed at PN14 in 
five different animals with one eye being injected with 10 nM TSA, while the other eye was sham 
injected. Eyes were immediately enucleated, fixed for 2 h in 4% PFA and prepared for cryosectioning 
(see ‘Retinal explant cultures’). Sections were labeled in a non-conclusive fashion to allow for an 
investigator-blind analysis.  
 
Microscopy, cell counting, and statistical analysis 
Fluorescence microscopy was performed on an Axio Imager Z1 ApoTome Microscope, equipped with 
a Zeiss Axiocam MRm digital camera. Images were captured using Zeiss Axiovision 4.7 software.  
Adobe Photoshop CS3 (Adobe Systems Incorporated, San Jose, CA, USA) was used for primary image 
processing. Quantifications were performed on pictures captured on at least nine different random 
positions of at least three sagittal sections for at least four different animals for each genotype and 
treatment using Z-stacks mode of Axiovision 4.7 at 20x magnification. The average area occupied by a 
photoreceptor cell (i.e. cell size) for each individual eye was determined by counting DAPI-stained nuclei 
 at U
nited A
rab Em
irates U
niversity on A
ugust 16, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
16 
 
in nine different areas (50 x 50 µm) of the retina. The total number of photoreceptor cells was estimated 
by dividing the outer nuclear layer (ONL) area by this average cell size. The quantification of cones was 
performed by manually counting the number of positively labelled cones in the ONL. Values obtained are 
given as fraction of total cell number in ONL (i.e. as percentage) and normalized to the wt situation. 
Values are expressed as average ± standard error of the mean (SEM). For statistical comparisons the two-
tailed, unpaired Student t-test as implemented in Prism 6 for Windows (GraphPad Software, La Jolla, CA, 
USA) was employed. 
To assess differences in cone migration, the distance in µm between the outer plexiform layer (OPL) 
and the center of Glyphos positive cell bodies was measured using Axiovision software (Zeiss). Distance 
values for 150-250 cones in the entire retinas were averaged on Glyphos immunostained sections from at 
least 5 different animals for each genotype. The migration profile of cones was presented as the relative 
migration distance to ONL thickness measured using Axiovision software. Statistical differences between 
experimental groups were calculated using Student’s two-tailed, unpaired t-test and Microsoft Excel 
software (Microsoft, Seattle, WA, USA). Error bars in the figures indicate SEM, levels of significance 
were: * = p<0.05, ** = p<0.01, *** = p<0.001.   
 
Assessment of intravitreal clearance of TSA 
The intravitreal clearance (CLivt) of TSA was calculated in silico using the Quantitative structure-
property relationships (QSPR) model published recently (56) based on comprehensive rabbit data from 
intravitreal injection experiments: LogCLivt= -0.25269 - 0.53747 (LogHD) + 0.05189 (LogD7.4), where 
HD is the number of hydrogen bond donor atoms and LogD7.4 is the calculated n-octanol/water 
distribution coefficient at pH 7.4 of the compound. The model is built based on small molecular weight 
compounds using the linear multivariate analysis tools: principal component analysis (PCA) and linear 
partial least square (PLS) (Simca Plus, version 10.5, Umetrics AB, Umea, Sweden). Firstly, the chemical 
structure of the TSA was retrieved from ACD/Dictionary from ACDlabs software (version 12, Advanced 
Chemistry Development, Inc., Toronto, Canada) and was used as input in ACDlabs software to generate 
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30 molecular descriptors: pKa for the most acidic molecular form, pKa for the most basic form, LogD at 
pH 5.5 and 7.4, LogP, MW, PSA (polar surface area), FRB (freely rotatable bonds), HD (hydrogen bond 
donors), HA (hydrogen bond acceptors), Htot (HD + HA), rule of 5, molar refractivity, molar volume, 
parachor, index of refraction, surface tension, density, polarizability, C ratio, N ratio, NO ratio, hetero 
ratio, halogen ratio, number of rings and number of aromatic, 3-, 4-, 5- and 6-membered rings. The 
applicability domain of the intravitreal clearance model for TSA was inspected generating the PCA score 
plot of the training set of the model together with TSA (Supplementary Fig. S2). Compounds that lie 
inside the ellipse depicted in the plot belong to the same chemical space of the model and are predictable 
by the model. Once the applicability domain was confirmed, the intravitreal clearance value of TSA was 
calculated with the above equation using the descriptors values (LogD at pH 7.4 and HD). Half-life was 
calculated using equation t1/2 = ln2 Vd/CL, where Vd is the volume of distribution and CL is the 
intravitreal clearance. For a brief discussion on the transferability between rabbit and mouse data, see 
supplementary note 1. 
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Figure legends 
Figure 1. HDAC inhibition protects cone photoreceptors in vitro. Long term retinal explant cultures 
from cpfl1 and wt animals were subjected to 10 nM TSA or control condition from PN14 to PN24. 
Glyphos staining (green), specific for cone photoreceptors, suggested that few cones survived at PN24 in 
untreated cpfl1 explant cultures (A), while TSA treated retinas displayed a clear increase in the numbers 
of cones (B). TSA treatment showed no adverse effect on wt treated retinas (C, D). The protective effect 
of TSA on cones is summarized in the bar graph (E). Error bars represent SEM; Scale bars are 20 µm. 
ONL-outer nuclear layer containing photoreceptors.  
Figure 2. HDAC inhibition protects degenerating cones in vivo. A single intravitreal injection of 1 nM 
or 10 nM TSA at PN14 was sufficient to significantly increase the number of cpfl1 mutant cones in 
treated compared to sham injected retinas at PN24 (A, B). In addition, cones from treated retinas were 
positioned mainly in the upper part of the ONL and had visibly longer inner segments (arrows), compared 
to sham treatment. In vivo treatment of wt animals showed no effects on the cone number, cone 
positioning, or structure (C, D). Quantification of the cone percentage of non-treated, sham treated, and 
TSA treated (1 nM and 10 nM) cpfl1 and wt animals is shown in the bar graph (E). Remarkably, the 
percentage of cones present was similar to wt for both TSA concentrations. Scale bar in a-d is 20 µm. 
ONL-outer nuclear layer. INL-inner nuclear layer containing interneurons. GCL-ganglion cell layer. 
Figure 3. Cpfl1 cones are protected also at PN30. Cone survival was analyzed in animals which had 
received a single intravitreal injection at PN14. At PN30 (i.e. 16 days post-injection) sham-treated cpfl1 
retina displayed a strong loss of cone-arrestin-labeled cones (green; A). By comparison, the 10nM TSA 
treatment preserved almost 90% of cones (B), similar to what was observed in age-matched wt (C).  The 
protective effect of TSA on cones is summarized in the bar graph (D). Error bars represent SEM; Scale 
bars are 20 µm. ONL-outer nuclear layer.  
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Figure 4. Cone specific opsins and transducin are expressed and correctly positioned in protected 
cones. In untreated PN24 cpfl1 retinas, cones were stained with Glyphos (green, A-C, D-F), and 
colocalized with M-opsin (magenta, G; merged, M), which was localized appropriately in only some of 
the cone outer segments, mainly in those positioned in the upper parts of the ONL. In the remaining cone 
cells, M-opsin was also mislocalized in what seemed to be cytoplasm of misplaced cones close to the 
border with the INL (arrows) and in cone end feet (arrowheads). A similar mislocalization was observed 
also with antibodies directed against S-opsin (H, N) and transducin (GNAT2; arrows; I, O). After TSA 
treatment, not only were there more cones, but also M-opsin (J, P), S-opsin (K, Q), as well as GNAT2 (L, 
R) were correctly localized almost exclusively in outer segments (P-R). Scale bar is 20 µm. ONL-outer 
nuclear layer. 
Figure 5. HDAC inhibition improves cone migration. cpfl1 retina displayed cone mislocalization, both 
in vitro and in vivo, when compared to wt (A-C). At PN24, cone nuclei were scattered throughout the 
ONL in cultured (A) and in vivo cpfl1 mutant retinas (B), while in wild-type retinas cones were positioned 
exclusively in the upper part of the ONL (C). TSA treatment significantly improved cone migration, both 
in the in vitro (D) and in vivo (E) treatment paradigms, while no effect was detectable in wt treated retinas 
(F). For quantification, the cone migration distance was assessed by measuring the distance between the 
center of cone nuclei from the outer plexiform layer (dashed line), relative to ONL thickness, measured 
for each individual section of analyzed retinas. The quantifications show a significant improvement of 
cone migration in vitro (G) and in vivo (H), with TSA treatment. Scale bars are 20 µm. ONL-outer 
nuclear layer.  
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Abbreviations 
HDAC histone deacetylase 
HAT histone acetyltransferases 
TSA Trichostatin A 
Cpfl1 cone photoreceptor function loss 1 
AMD age-related-macular degeneration 
DR diabetic retinopathy 
PDE phosphodiesterase  
cGMP 3’, 5’ -cyclic guanosine monophosphate 
PKG cGMP-dependent protein kinase 
VASP vasodilator-stimulated-protein 
GNAT2 cone specific transducin 
wt wild-type 
PFA paraformaldehyde 
PBS phosphate saline buffer 
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling 
ONL outer nuclear layer 
OPL outer plexiform layer 
IS inner segment 
DAPI 4',6-diamidino-2-phenylindole 
PN postnatal 
Glyphos Glycogen phosphorylase 
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HDAC inhibition protects cone photoreceptors in vitro.  
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HDAC inhibition protects degenerating cones in vivo.  
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Cpfl1 cones are protected also at PN30.  
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Cone specific opsins and transducin are expressed and correctly positioned in protected cones.  
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HDAC inhibition improves cone migration.  
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